Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis.
|
| Abstract |
We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 x 10(7) per kg was sufficient to achieve neutrophil (91%) and platelet recovery (86%), whereas the lower dose of NC achieved only 60 and 61%, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (>50 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32%, respectively (P=0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.
|
|---|---|
| Authors | T Nagamura-Inoue, S Kai, H Azuma, M Takanashi, K Isoyama, K Kato, S Takahashi, S Taniguchi, K Miyamura, K Aoki, M Hidaka, F Nagamura, A Tojo, Xm Fang, S Kato, Japan Cord Blood Bank Network |
| Journal | Bone marrow transplantation (Bone Marrow Transplant) Vol. 42 Issue 4 Pg. 241-51 (Aug 2008) ISSN: 0268-3369 [Print] England |
| PMID | 18574449 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!